Back to search
FDAFDA · Food and drugs·Recall number D-1217-2015

Capecitabine Tablets, USP, 500 mg, 120-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-2512-78, UPC 3 0378-2512-78 6.

Published July 15, 2015 · Recall initiated: June 30, 2015

Summary

FDA records drug Class II recall D-1217-2015, published July 15, 2015 and initiated June 30, 2015. Recalling firm: Mylan Pharmaceuticals Inc; Status: Terminated; Reported quantity: 1068 bottles; Lot: Lot #: 3053562, Exp 02/16. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: low out-of-specification (OOS) results for dissolution were obtained at the nine-month stability point.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc
Distributor
Nationwide
Lot
Lot #: 3053562, Exp 02/16
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Capecitabine Tablets, USP, 500 mg, 120-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-2512-78, UPC 3 0378-2512-78 6. recalled?

Yes. FDA published recall D-1217-2015 on July 15, 2015. Reported hazard: Failed Dissolution Specifications: low out-of-specification (OOS) results for dissolution were obtained at the nine-month stability point.

What should I do if I have this product?

Voluntary: Firm initiated · Letter